BRAIN and NERVE－神経研究の進歩71巻6号

2019年06月発行

特集 補体標的治療の現状と展望

重症筋無力症

著者： 鵜沢顕之¹ 桑原聡¹

所属機関： ¹千葉大学大学院医学研究院脳神経内科学

ページ範囲：P.565 - P.570

文献概要

重症筋無力症は主にアセチルコリン受容体に対する自己抗体によって神経筋接合部が障害される疾患であり，補体系が病態に強く関与している。近年，抗補体薬であるエクリズマブが，既存治療のみでは十分な症状の改善が得られない難治症例にも有効であることが示され，臨床応用されている。本論では重症筋無力症の病態における補体の関与，エクリズマブの作用機序・臨床効果，今後の展望について概説する。

参考文献

1)Meriggioli MN, Sanders DB: Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8: 475-490, 2009

2)Conti-Fine BM, Milani M, Kaminski HJ: Myasthenia gravis: past, present, and future. J Clin Invest 116: 2843-2854, 2006

3)Masuda M, Utsugisawa K, Suzuki S, Nagane Y, Kabasawa C, et al: The MG-QOL15 Japanese version: validation and associations with clinical factors. Muscle Nerve 46: 166-173, 2012

4)Utsugisawa K, Nagane Y, Akaishi T, Suzuki Y, Imai T, et al: Early fast-acting treatment strategy against generalized myasthenia gravis. Muscle Nerve 55: 794-801, 2017

5)Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, et al: Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16: 976-986, 2017

6)Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, et al: Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J Neurol 263: 1473-1494, 2016

7)Walport MJ: Complement. First of two parts. N Engl J Med 344: 1058-1066, 2001

8)Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L: Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 25: 1256-1264, 2007

9)Engel AG, Arahata K: The membrane attack complex of complement at the endplate in myasthenia gravis. Ann N Y Acad Sci 505: 326-332, 1987

10)Engel AG, Lambert EH, Howard FM: Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc 52: 267-280, 1977

11)Sahashi K, Engel AG, Lambert EH, Howard FM Jr: Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J Neuropathol Exp Neurol 39: 160-172, 1980

12)Soltys J, Kusner LL, Young A, Richmonds C, Hatala D, et al: Novel complement inhibitor limits severity of experimentally myasthenia gravis. Ann Neurol 65: 67-75, 2009

13)Zhou Y, Gong B, Lin F, Rother RP, Medof ME, et al: Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis. J Immunol 179: 8562-8567, 2007

14)Barohn RJ, Brey RL: Soluble terminal complement components in human myasthenia gravis. Clin Neurol Neurosurg 95: 285-290, 1993

15)Romi F, Kristoffersen EK, Aarli JA, Gilhus NE: The role of complement in myasthenia gravis: serological evidence of complement consumption in vivo. J Neuroimmunol 158: 191-194, 2005

16)Liu A, Lin H, Liu Y, Cao X, Wang X, et al: Correlation of C3 level with severity of generalized myasthenia gravis. Muscle Nerve 40: 801-808, 2009

17)Kusner LL, Kaminski HJ, Soltys J: Effect of complement and its regulation on myasthenia gravis pathogenesis. Expert Rev Clin Immunol 4: 43-52, 2008